{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:14:39Z","timestamp":1788250479579,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11060-026-05720-2","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T13:17:02Z","timestamp":1784726222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival, late toxicity and ability to return to work after proton radiotherapy for low-grade gliomas"],"prefix":"10.1007","volume":"179","author":[{"given":"Dominika","family":"Wojton-Dziewo\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Sk\u00f3ra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Anio\u0142","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Popow-Gierba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Kope\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Kisielewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mucha-Ma\u0142ecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"5720_CR1","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1158\/1078-0432.CCR-24-0901","volume":"30","author":"T van der Vaart","year":"2024","unstructured":"van der Vaart T et al (2024) Differences in the Prognostic Role of Age, Extent of Resection, and Tumor Grade between Astrocytoma IDHmt and Oligodendroglioma: A Single-Center Cohort Study. Clin Cancer Res 30:3837\u20133844","journal-title":"Clin Cancer Res"},{"key":"5720_CR2","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.prro.2022.05.004","volume":"12","author":"LM Halasz","year":"2022","unstructured":"Halasz LM et al (2022) Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol 12:370\u2013386","journal-title":"Pract Radiat Oncol"},{"key":"5720_CR3","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1093\/neuonc\/noac282","volume":"25","author":"JM Kros","year":"2023","unstructured":"Kros JM et al (2023) Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A\/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033\u201326033. Neuro Oncol 25:1443\u20131449","journal-title":"Neuro Oncol"},{"key":"5720_CR4","doi-asserted-by":"crossref","unstructured":"Tran S et al (2023) A threshold for mitotic activity and post-surgical residual volume defines distinct prognostic groups for astrocytoma IDH-mutant. Neuropathol Appl Neurobiol 49","DOI":"10.1111\/nan.12928"},{"key":"5720_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00066-016-1005-9","volume":"192","author":"SB Harrabi","year":"2016","unstructured":"Harrabi SB et al (2016) Dosimetrische Vorteile der Protonentherapie gegen\u00fcber der konventionellen Strahlentherapie mit Photonen bei jungen Patienten und Erwachsenen mit niedriggradigem Gliom. Strahlenther Onkol 192:759\u2013769","journal-title":"Strahlenther Onkol"},{"key":"5720_CR6","doi-asserted-by":"publisher","first-page":"e070071","DOI":"10.1136\/bmjopen-2022-070071","volume":"13","author":"LC Heggeb\u00f8","year":"2023","unstructured":"Heggeb\u00f8 LC et al (2023) Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH-mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden. BMJ Open 13:e070071","journal-title":"BMJ Open"},{"key":"5720_CR7","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","volume":"374","author":"JC Buckner","year":"2016","unstructured":"Buckner JC et al (2016) Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med 374:1344\u20131355","journal-title":"N Engl J Med"},{"key":"5720_CR8","doi-asserted-by":"publisher","unstructured":"Bell EH et al (2020) Comprehensive genomic analysis in NRG oncology\/RTOG 9802: a phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade Glioma. J Clin Oncol 38. https:\/\/doi.org\/10.1200\/jco.19.02983","DOI":"10.1200\/jco.19.02983"},{"key":"5720_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11060-024-04829-6","volume":"171","author":"J Rincon-Torroella","year":"2025","unstructured":"Rincon-Torroella J et al (2025) Impact of upfront adjuvant chemoradiation on survival in patients with molecularly defined oligodendroglioma: the benefits of PCV over TMZ. J Neurooncol 171:35\u201345","journal-title":"J Neurooncol"},{"key":"5720_CR10","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.ijrobp.2008.06.784","volume":"72","author":"G Cairncross","year":"2008","unstructured":"Cairncross G et al (2008) A randomized trial of chemotherapy plus radiotherapy (rt) versus rt alone for anaplastic oligodendroglioma (RTOG 9402): the perspective of longer follow-up. Int J Radiat Oncol Biol Phys 72:S7\u2013S8","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"5720_CR11","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","volume":"41","author":"PY Wen","year":"2023","unstructured":"Wen PY et al (2023) RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol 41:5187\u20135199","journal-title":"J Clin Oncol"},{"key":"5720_CR12","doi-asserted-by":"publisher","first-page":"S580","DOI":"10.21037\/tcr.2019.11.16","volume":"8","author":"JM Slater","year":"2019","unstructured":"Slater JM, Shih HA (2019) Pseudoprogression in low-grade glioma. Transl Cancer Res 8:S580\u2013S584","journal-title":"Transl Cancer Res"},{"key":"5720_CR13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11060-025-04973-7","volume":"173","author":"HL van der Weide","year":"2025","unstructured":"van der Weide HL et al (2025) Neurocognitive function in lower grade glioma patients selected for proton radiotherapy: real-world data from a prospective cohort study. J Neurooncol 173:147\u2013156","journal-title":"J Neurooncol"},{"key":"5720_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11060-026-05582-8","volume":"177","author":"JC Kennedy","year":"2026","unstructured":"Kennedy JC, Price SJ, Manly T, Woodberry E, Burton M (2026) Returning to work after treatment for a low-grade glioma: analysing return-to-work rates and exploring barriers experienced by patients. J Neurooncol 177:117","journal-title":"J Neurooncol"},{"key":"5720_CR15","doi-asserted-by":"publisher","first-page":"110594","DOI":"10.1016\/j.radonc.2024.110594","volume":"202","author":"BG Baumert","year":"2025","unstructured":"Baumert BG et al (2025) ESTRO-EANO guideline on target delineation and radiotherapy for IDH-mutant WHO CNS grade 2 and 3 diffuse glioma. Radiother Oncol 202:110594","journal-title":"Radiother Oncol"},{"key":"5720_CR16","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2340\/1651-226X.2025.43883","volume":"64","author":"JF Kallehauge","year":"2025","unstructured":"Kallehauge JF, Gr\u00f8ndahl S, Byskov CS, H\u00f8yer M, Lukacova S (2025) Prediction model for the selection of patients with glioma to proton therapy. Acta Oncol 64:889\u2013893","journal-title":"Acta Oncol"},{"key":"5720_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijrobp.2019.01.003","volume":"104","author":"L Dirven","year":"2019","unstructured":"Dirven L et al (2019) Impact of Radiation Target Volume on Health-Related Quality of Life in Patients With Low-Grade Glioma in the 2-Year Period Post Treatment: A Secondary Analysis of the EORTC 22033\u201326033. Int J Radiation Oncology*Biology*Physics 104:90\u2013100","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"5720_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s11060-015-1952-5","volume":"126","author":"JC Sherman","year":"2016","unstructured":"Sherman JC et al (2016) Neurocognitive effects of proton radiation therapy in adults with low-grade glioma. J Neurooncol 126:157","journal-title":"J Neurooncol"},{"key":"5720_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.radonc.2019.04.027","volume":"137","author":"S Tabrizi","year":"2019","unstructured":"Tabrizi S et al (2019) Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma. Radiother Oncol 137:95\u2013101","journal-title":"Radiother Oncol"},{"key":"5720_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013047.pub2","author":"TA Lawrie","year":"2019","unstructured":"Lawrie TA et al (2019) Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma. Cochrane Database Syst Reviews. https:\/\/doi.org\/10.1002\/14651858.CD013047.pub2","journal-title":"Cochrane Database Syst Reviews"},{"key":"5720_CR21","doi-asserted-by":"crossref","unstructured":"Weber DC et al (2020) Proton therapy for brain tumours in the area of evidence-based medicine. Br J Radiol 93","DOI":"10.1259\/bjr.20190237"},{"key":"5720_CR22","doi-asserted-by":"crossref","unstructured":"Mcnamara A, Paganetti H (2020) Proton therapy special feature: review article modelling variable proton relative biological effectiveness for treatment planning","DOI":"10.1259\/bjr.20190334"},{"key":"5720_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.10.025","author":"MJ Pelak","year":"2025","unstructured":"Pelak MJ et al (2025) Patient-Reported Outcomes, Neurocognitive Functioning, and Oncologic Results of Pencil-Beam-Scanning Proton Beam Therapy for CNS WHO G2 and G3 IDH1-Mutant Diffuse Adult Glioma: A Single Institution Experience. Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.10.025","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05720-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05720-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05720-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:27:05Z","timestamp":1788247625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05720-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5720"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05720-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9986919\/v1","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"9 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"9"}}